We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0HS8 market cap is 33.82M. The company's latest EPS is USD -2.5571 and P/E is -1.11.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20.09M | -19.15M | -29.05M | -57.6M | -25.71M |
| Net Income | -19.36M | -8.15M | -27.47M | -54.23M | -20.84M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 27.15M | 36M | 97.01M | 73.03M | 54.69M |
| Total Liabilities | 6.6M | 3.76M | 5.01M | 6.71M | 6.8M |
| Total Equity | 20.55M | 32.24M | 92M | 66.32M | 47.89M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -18.88M | -8.82M | -22.25M | -21.17M | -20.03M |
| Investing | 21.43M | -7.28M | -54.9M | 28.91M | 10.1M |
| Financing | 1.18M | 18.58M | 85.28M | -224k | 385k |
| Market Cap | 33.82M |
| Price to Earnings Ratio | -1.11 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.02 |
| Price to Book Ratio | 0.48 |
| Dividend Yield | - |
| Shares Outstanding | 8.15M |
| Average Volume (1 week) | 145 |
| Average Volume (1 Month) | 159 |
| 52 Week Change | 0.00% |
| 52 Week High | 4.15 |
| 52 Week Low | 4.15 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Lisata Therapeutics Inc |
| Address |
651 n broad st suite 201 wilmington, delaware 19709 |
| Website | https://www.caladrius.com |
| Industry | insurance carriers, nec (6399) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
